What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging Interesting findings by Dr MDanila et al: 👉In-person visits due to org/clinic level influences 👉#telemedicine visits due to individual level influences #ACR22 @RheumNow ABST0193 https://t.co/HcCUeahH8L

Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASDAI score in women with AS. Morning stiffness has the highest classification value #ABS0374 #ACR22 @RheumNow https://t.co/DozZ6bxSU3

Rhee et al. MRI can, and frequently does, visualise enhancement in multiple cranial arteries @rheumnow #ACR22 Abstr#0473 https://t.co/iTtvl2DSoi https://t.co/tUV2zYIO8y

• Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients …

Brunetta et al. Is serum ANCA assoc malignancy? No @rheumnow #ACR22 Abstr#0450 https://t.co/dCJUZVvAqy https://t.co/K27Rk5tLSU

• Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retr…

Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR 1.17) higher risk than controls, RA, or PsO/PsA @rheumnow #ACR22 Abstr#0062 https://t.co/PbRa033e0L https://t.co/ENycKG4cyQ

• Comparing Alzheimer's Disease Risk in Patients with Chronic Inflammatory A…

Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an interesting study yielding more questions than answers. #ACR22 @RheumNow https://t.co/0Q260CGw3r https://t.co/LepPOrq7Gv

• Sarcoidosis Incidence After mTOR Inhibitor Treatment - ACR Meeting Abstracts

Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474 https://t.co/jPRy4RjfJA https://t.co/b1CP8pFwhJ

• Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multi…

Adding MTX to Pegloticase for 52 wks in gout ◦ Improved response rate by 30% ◦ Reduced discontinuation rate by 40% ◦ Greater resolution of tophi by 20% ◦ Similar safety profile in MTX vs non-MTX groups Botson J MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+. Less likely MSK symptoms, granulomatous disease @rheumnow #ACR22 Abstr#0439 https://t.co/Zi7H5UaolS https://t.co/Z04TvugnnE

• Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and W…

#abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr

de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west gradient @rheumnow #ACR22 Abstr#0475 https://t.co/XDSSrJcMu5 https://t.co/nlJjcPB3zo

• Whole-country and Regional Incidences of Giant Cell Arteritis in French Contine…

Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI >4, +HLA-B27, female sex, ^ CRP, hx of B ocular involvement. #ACR22 @RheumNow https://t.co/Fg0v6NVQcI

• Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis…

Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concerns most common reason at 52%. For booster, lack of recommendation from physician biggest factor at 39%. @rheumnow #ACR22 Abstr#0083 https://t.co/ISdTmOjIWs https://t.co/Qr47Or2a6v

• COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Pract…

Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving improved communication @rheumnow #ACR22 Abstr#0063 https://t.co/sFU1FzLUfB https://t.co/9AIOijpI0j

• Implementability of a SLE Medication Adherence Intervention - ACR Meeting Abstr…

#abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0